TGA regulation can help you check whether a therapeutic good is included in the Australian Register of Therapeutic Goods, or whether another lawful access pathway is relevant. It does not decide personal suitability. In consultation, also ask about the supply source, identity, expiry, storage, patient record and the response to a recall or suspected adverse event.
Start with the question you really want answered
If you are wondering whether a clinic can explain what it proposes to use, that is a reasonable question to bring to consultation. You do not need to arrive knowing a product name or interpreting a register entry on your own.
Corey can first clarify the concern you want assessed. If a therapeutic good becomes relevant, you can then ask about its regulatory status, lawful supply and the clinic records that connect it to your care.
Use five checks, not one badge
| Check | A useful question | What you are listening for |
|---|---|---|
| 1. Status | Is it in the ARTG, or does another lawful pathway apply? | A specific explanation relevant to the proposed good. |
| 2. Source | How did the clinic obtain it? | An authorised and traceable supply route. |
| 3. Identity | How is it linked to my record? | Identity, batch or lot, and expiry where relevant. |
| 4. Handling | How are its storage requirements followed? | A monitored process, not a vague reassurance. |
| 5. Response | What happens after a defect, recall or suspected adverse event? | A clear clinic contact, record and reporting route. |
What the ARTG can tell you
The Australian Register of Therapeutic Goods is the public database of therapeutic goods that can be legally supplied in Australia. An entry can include the product name and formulation details, sponsor, manufacturer and public documents where available.
That is useful evidence about the good. It is not a personal recommendation, proof that a proposed use suits you or proof of how an individual clinic sourced, stored and recorded it. Those questions still belong in the consultation.
If there is no ARTG entry
Which pathway is relevant?
The TGA permits limited access to some unapproved therapeutic goods through pathways including the Special Access Scheme, Authorised Prescriber pathway and clinical trials.
What has the TGA evaluated?
An unapproved good has not been evaluated through the ordinary ARTG route for quality, safety or effectiveness. The status and implications need a clear personal discussion.
Does it suit this situation?
Lawful access and personal suitability are different questions. Assessment, alternatives, material risks and consent still matter.
Why product details may wait until consultation
Some therapeutic goods, including prescription medicines and unapproved goods, cannot be advertised to the public. A clinic can still explain the specific proposed good, alternatives, material risks and relevant regulatory status privately after assessment. The absence of a public product menu should not prevent a clear consent conversation.
For the separate advertising question, read the cosmetic clinic advertising guide.
Ask for a traceable supply story
A useful answer goes beyond an apparently sealed box or the word “genuine”. Ask whether the clinic uses an authorised Australian supply route and can connect the item to the relevant supplier or sponsor record.
Receipt and stock records, identity and expiry checks, separation of unsuitable stock, and a way to identify affected patients after a defect or recall form a traceable story. The exact record requirements depend on the good and the applicable law.
Storage should be explainable without a back-room tour
Storage is not one universal temperature. The clinic should follow the approved instructions and any relevant professional, legal and facility requirements for the particular good.
You can ask who monitors the required conditions, how a deviation is recognised, what happens to affected stock and how expiry or opening dates are controlled where relevant. The point is a documented process, not access to a cupboard or refrigerator.
Connect the product, practitioner and record
The TGA regulates therapeutic goods. Ahpra and National Boards regulate registered practitioners. Clinic systems cover matters such as consent, stock handling, records and follow-up. One check cannot stand in for all three.
If care proceeds, the record should be sufficient to reconstruct what was supplied or administered. Depending on the good and context, this may include its identity, amount, site, date, batch or lot, expiry, supplier or prescriber information and the people involved.
The practical test is simple: could the clinic connect the patient and affected stock if a defect, recall, complaint or suspected adverse event needed investigation?
What TGA regulation does not decide
- that a person is suitable for a cosmetic procedure
- that a practitioner has the necessary competence or scope
- that consent was voluntary and sufficiently informed
- that the item was sourced, stored and handled correctly at this clinic
- that an expected appearance change will occur
- that every adverse event was caused by the therapeutic good
Regulation narrows uncertainty; it does not remove clinical judgement, system responsibility or individual variation.
A broad claim is an opening, not the whole answer
If a clinic relies on “TGA approved” as its whole answer, ask which ARTG entry or lawful access explanation applies to the proposed good. Then ask who supplied it, how it is identified in the record, which storage instructions apply and how the clinic would respond to a recall.
A regulatory reference can be accurate and still incomplete. You are entitled to enough information to understand the proposed care and take time with the decision.
Know which response you need
A defect can involve manufacture, packaging, storage or handling. A recall or other market action is a coordinated response to a product issue. A suspected adverse event is a harmful or unintended problem associated with a therapeutic good, but it does not by itself prove the good caused the problem.
The TGA accepts reports about safety problems and adverse events. If symptoms are urgent, seek appropriate clinical care first. A regulatory report does not replace emergency assessment or the clinic’s immediate review responsibilities.
Bring a six-line note to consultation
- Proposed good: the specific identity explained privately after assessment.
- Status: ARTG entry or lawful access pathway.
- Source: authorised supply route and traceability.
- Record: identity, expiry, batch or lot and administration details where relevant.
- Handling: applicable storage instructions and response to a deviation.
- Problem route: clinic contact, urgent care boundary, recall process and TGA report pathway.
If one line remains blank, ask for clarification before making the decision.
What to expect at your visit
You will meet directly with Corey for a calm, private discussion about your concern and the questions you want answered.
Corey first assesses what you are asking about. If a therapeutic good becomes relevant, you can discuss its specific regulatory status, lawful supply, clinic records, alternatives, material risks and whether you would prefer to proceed, wait or stop there.
Choose the guide that matches your question
What can I verify?
Stay on this page for ARTG status or lawful access, supply, identity, storage, records and reporting.
Can I trust what I see online?
Use the cosmetic clinic advertising guide for website language, images, links and pressure signals.
Who regulates which part?
Use the regulation and scope guide to separate product, practitioner, service and advertising concerns.
Official sources behind this guide
The key claims on this page are supported by current primary guidance from the Therapeutic Goods Administration and the Ahpra public register.
- TGA: About the Australian Register of Therapeutic Goods
- TGA: Product regulation according to risk
- TGA: Access unapproved products for consumers
- TGA: What can and cannot be advertised to the public
- TGA: Report a problem with a therapeutic good
- TGA: Report an adverse event or safety problem
- Ahpra public register
Sources were checked on 3 August 2026. They explain the regulatory framework and public reporting routes. They do not establish the status, suitability or legality of a specific item without its identifying information and context.
Bring the question, not a commitment
You can meet Corey, understand which regulatory details apply and take time to decide whether any next step feels right for you.
Is this for you?
Consider booking a consultation if
- Adults who want to understand an ARTG entry or lawful access explanation
- Patients asking about authorised supply, storage, traceability and recall records
- Readers separating product regulation from practitioner and clinic accountability
- People preparing factual questions before an individual consent decision
This may not be for you if
- Anyone seeking public promotion or comparison of prescription medicines
- People treating TGA status as proof of personal suitability
- Anyone using a regulatory report instead of urgent health care
- People seeking a legal finding about a specific clinic or product without identifying evidence
Suitability is confirmed at consultation. This list is general guidance, not a substitute for clinical assessment.
Frequently asked questions
What is the ARTG?
The Australian Register of Therapeutic Goods is the public database of goods that can be supplied in Australia. It can show product, sponsor, manufacturer and supporting information. An entry does not decide whether that good is suitable for one person or prove how a clinic handled it.
Does no ARTG entry always mean illegal supply?
No. The TGA permits limited lawful access to certain unapproved goods through pathways such as the Special Access Scheme, Authorised Prescriber pathway and clinical trials. The relevant practitioner should explain the status, access route and implications in the individual consent discussion.
Why does this page not name cosmetic prescription products?
TGA rules prohibit public advertising of prescription medicines and unapproved therapeutic goods. Product names, nicknames, indirect references, links and promotional effects can matter. Specific information can be discussed privately after assessment when it is relevant to informed consent.
What does TGA regulation not prove?
It does not prove personal suitability, practitioner competence, adequate consent, correct clinic storage, a particular outcome or that a later symptom was caused by the good. Product regulation, practitioner regulation and clinic systems answer different parts of the safety question.
How can I ask about product storage without inspecting the clinic?
Ask which manufacturer storage instructions apply, who monitors them, how deviations are identified, what happens to affected stock and how expiry or opening dates are controlled where relevant. A documented process is more meaningful than a photograph of a cupboard or refrigerator.
Which product details may matter in my clinical record?
Depending on the good and context, useful traceability details can include the name, dose or amount, site, date, batch or lot, expiry, supplier or prescriber information and people involved. The record should support review, recall, defect and adverse event investigation.
Is a TGA logo or “approved” statement enough?
No. Ask for the relevant ARTG entry or lawful access explanation, then check supply source, identity, handling, record and problem response. A broad regulatory statement may be accurate but still incomplete for an individual decision.
What is the difference between a defect and an adverse event?
A defect concerns the product or its manufacture, packaging, storage or handling. An adverse event is a suspected harmful or unintended problem associated with a therapeutic good. An adverse event does not automatically prove that the good caused the problem.
Can a consumer report a suspected adverse event to the TGA?
Yes. The TGA accepts consumer and health professional reports about adverse events and safety problems. Seek appropriate clinical or emergency care first when symptoms are urgent. A regulatory report does not replace assessment or the clinic’s immediate review pathway.
Who regulates the practitioner rather than the product?
Ahpra and the relevant National Board regulate registered health practitioners. The TGA regulates therapeutic goods and their advertising. State or territory bodies may handle health service complaints. Use the official route matching the product, practitioner, service or advertising concern.
Clinical references
- About the Australian Register of Therapeutic Goods
- Product regulation according to risk
- Access unapproved products for consumers
- What can and cannot be advertised to the general public
- Report a problem with a therapeutic good
- Report an adverse event or safety problem
- Ahpra public register of practitioners